PERSPECTIVES OF TREATMENT OF TERMINAL LIVER DISEASE IN CHRONIC HCV-INFECTION

Abstract

Aim. Assessment of role of HBV viral proteins in liver disease progression in chronic HCV-infected patients.Methods. 2934 patients were included into the study, in whom serological markers of HBV- and HCV-infection were evaluated. 80 patients were randomly selected for determination of role of anti-HBcor in progression of HCV-induced chronic liver disease. Role of latent HBV-infection in development of hepato-cellular carcinoma was assessed in 28 liver transplant recipients with chronic HCV-infection.Results. Serological markers of HBV- and/or HCV-infection were detected in 28%. Presence of anti-HBcor IgG was significantly oftener registered in patients with anti-HCV-antibodies (81 vs 17% in absence of anti-HCV-antibodies, p<0,05). Presense of anti-HBcor antibodies did not influenced significantly the activity of liver damage. In HCV-infected liver transplant recipients HBV DNA in liver tissue could be detected in absence of HBs-antigene. anti-HBcor was associated with trend of increasing of risk of hepato-cellular carcinoma development.Conclusion. All potential liver donors should be examined for anti-HBV- and anti-HCV-antibodies presence.

Keywords

• chronic hcv-infection
• outcomes
• liver cirrhosis
• liver transplantation